What You Should Know:
– Cybin Inc. (NYSE American: CYBN), a company developing next-generation psychedelic therapies for mental health, has secured $150M in a private placement of common shares led by Deep Track Capital and included participation from other institutional investors. The price per share was set at $0.43, representing a 17% premium over the 10-day volume-weighted average trading price.
– The funding will fuel the development of CYB003, a potential first-in-class psychedelic treatment for major depressive disorder (MDD).
Developing Differentiated, Next-Gen Psychedelic Therapeutics
Founded in 2019, Cybin is a clinical-stage biopharmaceutical company dedicated to developing safe and effective psychedelic treatments for mental health conditions. Their approach leverages a network of experts and innovative technologies to advance psychedelic drug discovery, delivery systems, and treatment protocols. Cybin’s current pipeline includes:
- CYB003: Deuterated psilocybin for major depressive disorder (Phase 3 development)
- CYB004: Deuterated DMT molecule for generalized anxiety disorder
- Additional investigational psychedelic compounds
Significant Milestone for Psychedelic Medicine
This $150M investment is a significant step forward for Cybin and the field of psychedelic medicine. With successful Phase 3 trials, CYB003 could be the first FDA-approved psychedelic therapy for MDD. The private funds will primarily support Phase 3 trials for CYB003, a deuterated psilocybin analog targeting depression. The Canadian-based company currently operates in the US, UK, Netherlands, and Ireland.
